Anke Schultz
Papers
1
Total Citations
20
H-Index
1
About
Anke Schultz is a pivotal figure in HIV vaccine research, specializing in virology and assay standardization for global clinical trials. Her most impactful contribution is the development of an automated HIV-1 Env-pseudotyped virus production system, detailed in her 2012 paper (20 citations), which revolutionized the scalability and reproducibility of neutralization assays. This work directly addressed a critical bottleneck in vaccine development by enabling standardized, high-throughput assessments of immune responses across international trials. Schultz’s innovations have been instrumental in prioritizing vaccine candidates by ensuring consistent, comparable data from diverse study sites. Her efforts bridge laboratory science and clinical application, providing the robust tools necessary for evaluating HIV vaccine efficacy. Beyond this key achievement, her research continues to refine assay methodologies, reducing variability and accelerating the path toward an effective vaccine. Schultz’s work has had a lasting impact on the field, empowering researchers to conduct more reliable and collaborative studies, and her contributions remain foundational to the global fight against HIV/AIDS.
Research Focus
Key Achievements
Top Papers
- 1